

[Imipenem + cilastatin](#)

Not recommended as an essential medicine

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.2. Watch group antibiotics](#)

ATC codes: [J01DH51](#)

EMLc

Indication

Pseudomonas aeruginosa resistant to other antibiotic ICD11 code: [MG50.8Y](#)

INN

Imipenem + cilastatin

Medicine type

Chemical agent

Antibiotic groups

[WATCH](#)

List type

Complementary

Formulations

Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection ; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

EML status history

First added in 1997 ([TRS 882](#))

Changed in 2002 ([TRS 914](#))

Changed in 2007 ([TRS 950](#))

Changed in 2009 ([TRS 958](#))

Removed in 2017 ([TRS 1006](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Imipenem + cilastatin](#)

DrugBank

[Imipenem](#),

[Cilastatin](#)

Summary of evidence and Expert Committee recommendations

As part of the syndrome-based comprehensive review of antibacterials on the Model Lists, imipenem + cilastatin was removed from the EML and EMLc. However, it is acknowledged in the lists as an alternative to meropenem except for acute bacterial meningitis where meropenem is preferred.